ANDA 91658, held by Teva Pharmaceuticals. Voriconazole.
As of Nov 21, 2026, ANDA 91658 (Voriconazole), held by Teva Pharmaceuticals, was first approved by FDA on Apr 6, 2012, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2012 | Original application | Approved | None posted |
| Voriconazole50MG · tablet;oral | Voriconazole | Discontinued |
| Voriconazole200MG · tablet;oral | Voriconazole | Discontinued |
| Jul 23, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 23, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 23, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 23, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jan 21, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 21, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 6, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters